如何延长急性缺血性卒中溶栓治疗时间窗？  

How to extend the thrombolytic time window for acute ischernic stroke？

作　　者：武晓宁[1,2] 闵连秋[2] 罗玉敏[1] 

机构地区：[1]首都医科大学宣武医院脑血管病研究所,北京110005 [2]辽宁医学院附属第一医院神经内科,锦州121001

出　　处：《国际脑血管病杂志》2012年第5期362-367,共6页International Journal of Cerebrovascular Diseases

基　　金：国家自然科学基金（81071058）

摘　　要：溶栓治疗目前是急性缺血性卒中最有效的治疗方法，发病3h内静脉给予重组组织型纤溶酶原激活剂是唯一被美国食品和药品监督管理局批准用于急性缺血性卒中治疗的药物。不过，由于静脉溶栓治疗的时间窗很短，只有极少数患者能在发病3h内到达医院并接受静脉溶栓治疗。因此，如何延长溶栓治疗时间窗，使更多的患者有机会接受溶栓治疗并从中获益，是学者们一直关注的问题。文章对近年来有关延长溶栓治疗时间窗的研究进展进行了综述。Currently, thrombolytic therapy is the most effective treatment for acute ischemic stroke. Intravenous recombinant tissue plasminogen activator administered within 3 hours of symptom onset is the only medication approved by U.S. Food and Drag Administration for the treatment of acute ischemic stroke. However, because the time window for intravenous thrombolytic therapy is very short, only a very few patients can reach the hospital for intravenous thrombolytic therapy within 3 hours of onset. Therefore, how to extend the time window of thrombolytic therapy for more patients to have accessed to it and benefit from it have been the concern of researchers. This article reviews about the recent advances in research on extending the time window of thrombolytic therapy.

关 键 词：卒中 脑缺血 溶栓疗法 纤维蛋白溶解药 神经保护药 时间因素 

分 类 号：R743.3[医药卫生—神经病学与精神病学]